A phase I/IIa trial of of a novel therapeutic anti-cancer DNA vaccine, Elenagen in terminally ill cancer patients
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2017
Price : $35 *
At a glance
- Drugs P62-cancer-dna-vaccine CureLab Oncology (Primary)
- Indications Breast cancer; Cancer; Ovarian cancer
- Focus Adverse reactions
- 05 Apr 2017 New trial record
- 28 Mar 2017 According to a CureLab Oncology media release, results from this trial have been published in Oncotarget.
- 28 Mar 2017 Results published in a CureLab Oncology media release.